UPDATED Jun 15, 2023
Investing in companies that think about the future will generate eco-friendly products and sustainable returns. As consumers become more environmentally-aware, demand will increase for these companies' products.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
DVRGDeepVerge | UKĀ£0.0023 | -24.6% | -98.0% | UKĀ£1.9m | n/a | PB0.08x | n/a | n/a | ||
BSFABSF Enterprise | UKĀ£0.12 | -11.3% | 88.0% | UKĀ£12.1m | n/a | PB3.4x | n/a | n/a | ||
ROQRoquefort Therapeutics | UKĀ£0.068 | -1.8% | -15.6% | UKĀ£8.7m | n/a | PB1.2x | n/a | n/a | ||
APTAAptamer Group | UKĀ£0.14 | 55.6% | -85.6% | UKĀ£9.7m | UKĀ£1.80 | PS2.6x | S-6.4% | n/a | ||
SNGSynairgen | UKĀ£0.075 | -8.5% | -72.3% | UKĀ£15.1m | UKĀ£2.20 | PB0.7x | n/a | n/a | ||
EVGEvgen Pharma | UKĀ£0.031 | -13.9% | -11.4% | UKĀ£8.5m | n/a | PS19.3x | n/a | n/a | ||
PRMProteome Sciences | UKĀ£0.06 | 21.1% | 79.9% | UKĀ£17.8m | n/a | PE13.4x | n/a | n/a | ||
NFXNuformix | UKĀ£0.0025 | 4.2% | -28.6% | UKĀ£1.8m | n/a | PB0.4x | n/a | n/a | ||
INCIncanthera | UKĀ£0.066 | 0% | -7.1% | UKĀ£5.2m | n/a | PB12.1x | n/a | n/a | ||
VALValiRx | UKĀ£0.092 | 5.7% | -57.5% | UKĀ£8.3m | n/a | PB2.1x | n/a | n/a | ||
BDRXBiodexa Pharmaceuticals | UKĀ£0.037 | -16.7% | -98.5% | UKĀ£3.5m | n/a | PS5.5x | n/a | n/a | ||
OPTIOptiBiotix Health | UKĀ£0.075 | -3.2% | -65.1% | UKĀ£6.8m | n/a | PE1.2x | n/a | n/a | ||
GDRgenedrive | UKĀ£0.17 | -4.2% | -16.9% | UKĀ£17.1m | n/a | PS251.3x | n/a | n/a | ||
ONCOncimmune Holdings | UKĀ£0.18 | -16.1% | -80.2% | UKĀ£13.3m | n/a | PS4.4x | n/a | n/a | ||
ETXe-therapeutics | UKĀ£0.22 | 9.9% | 37.7% | UKĀ£128.2m | n/a | PS269.9x | n/a | n/a | ||
4BB4basebio | UKĀ£5.75 | 1.8% | 38.6% | UKĀ£69.0m | UKĀ£12.00 | PS264.3x | n/a | n/a | ||
FUMFutura Medical | UKĀ£0.52 | 21.9% | 72.4% | UKĀ£154.9m | UKĀ£1.18 | PB32.8x | n/a | n/a | ||
PBXProBiotix | UKĀ£0.05 | 0% | -76.7% | UKĀ£6.1m | n/a | n/a | n/a | n/a | ||
CELCeladon Pharmaceuticals | UKĀ£1.58 | 0% | 53.7% | UKĀ£97.1m | UKĀ£2.10 | PS4047.1x | n/a | n/a | ||
GENFGenflow Biosciences | UKĀ£0.03 | -1.6% | 17.3% | UKĀ£8.9m | n/a | PB3.8x | n/a | n/a | ||
IMMImmuPharma | UKĀ£0.032 | 1.1% | -43.1% | UKĀ£10.8m | n/a | PB4.3x | n/a | n/a | ||
KNBKanabo Group | UKĀ£0.022 | 12.5% | -35.7% | UKĀ£9.5m | n/a | PS15.8x | n/a | n/a | ||
HEMOHemogenyx Pharmaceuticals | UKĀ£0.012 | -2.0% | -9.3% | UKĀ£14.0m | n/a | PB4.3x | n/a | n/a | ||
SARSareum Holdings | UKĀ£1.33 | -1.9% | -30.3% | UKĀ£90.2m | UKĀ£3.04 | PB31.3x | E47.0% | n/a |